Vertex PharmaceuticalsVRTX

Vertex Pharmaceuticals 8-K

Filing date · Nov 2, 2026

The company said total revenue for Q3 2026 rose to $3.44 billion, up 12% from Q3 2025. It cited continued performance of cystic fibrosis (CF) therapies and exp…

Continue to the filing details and any available analysis after signing in.

Filing lists and official source links are available without signing in.

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.

Sign in to read this filing in detail